Navigation Links
Magid Abou-Gharbia, Ph.D., FRSC Joins LAXAI as Scientific Advisor
Date:8/27/2009

SOUTH PLAINFIELD, N.J., Aug. 27 /PRNewswire/ -- LAXAI, a Leading Contract Research Organization based in the U.S. and India providing integrated services across the drug discovery and development spectrum, today announced that Magid Abou-Gharbia, Ph.D., FRSC has joined the company as its Scientific Advisor.

Naren Mallakunta, CEO of LAXAI, welcomed Magid by saying, "It is a privilege to have Magid Abou-Gharbia as our Scientific Advisor. His extensive knowledge and experience in the Global Research Pharmaceutical Industry will guide LAXAI in its endeavor to offer more value based integrated/collaborative research services to our Biopharmaceutical Clients."

"I am pleased to join LAXAI as its Scientific Advisor. LAXAI with their strong management team and experienced staff is regarded among the leaders in contract research and outsourcing services," said Professor Abou-Gharbia. "The Moulder Center for Drug Discovery Research at the School of Pharmacy, Temple University is pleased to enter into a strategic partnership with LAXAI in the areas of Medicinal Chemistry, Biology and Integrated/Collaborative Research. LAXAI is an ideal partner for biotech and major Pharma to increase medicinal chemistry capacity and complement internal in-house Drug Discovery resources," said Professor Abou-Gharbia

Dr. Abou-Gharbia is the Associate Dean for Research, Professor of Medicinal Chemistry and Director of the Moulder Center for Drug Discovery Research (MCDDR) at the School of Pharmacy, Temple University. Prior to joining Temple University in 2008, Dr. Abou-Gharbia spent 26 years at Wyeth Pharmaceuticals where he was Senior Vice President and Head of Chemical Screening Sciences. He was responsible for overseeing and directing the chemistry and screening research efforts of over 500 scientists at four U.S. research facilities and one in Hyderabad, India in support of drug discovery in neuroscience, inflammation, women's health/bone, oncology and cardiovascular disease. His research efforts resulted in 100 U.S. patents and over 350 worldwide patents and contributed to the discovery of several marketed drugs and many compounds currently under clinical evaluation including two SNRI anti-depressants, Effexor(R) and Pristiq(R), an anticancer rapamycin derivative, Torisel(R), a broad spectrum antibiotic, Tygacil(R), and a selective estrogen receptor modulator, bazedoxifene. Dr. Abou-Gharbia received his Ph.D. in Organic Chemistry from the University of Pennsylvania. After a two year NIH Postdoctoral Fellowship at Temple University, he joined Wyeth. Dr. Abou-Gharbia will provide expertise and insight into strategies and medicinal chemistry approaches utilized in the design of novel small molecules CNS therapeutics. His numerous awards include: Induction to ACS Medicinal Chemistry Hall of Fame (2008); ACS Heroes of Chemistry (2008); Alfred Burger Award in Medicinal Chemistry (2008); Science and Technology Medal from the R&D Council of New Jersey (2008); selected among the Top 10 Scientists in New Jersey by New Jersey Business Magazine (2008); American Institute of Chemists (AIC) Chemistry Pioneer Award (2007); Fellow of the Royal Society of Chemistry (FRSC 2006); Researcher of the Year (2006) from Health Care Institute of NJ (HINJ); Trailblazer Award (2006) from Science Spectrum; Induction into the New Jersey Inventors Hall of Fame (2004); The Procter Medal (2003); ACS Earle B. Barnes Award (2001); Philadelphia Organic Chemists Club (POCC) Award (2001); Egyptian Pharmaceutical Society Drug Discovery Award (2000);Named as one of the most Prolific Inventors of the Decade by US Patent & Trade Mark (1998); ACS-Philadelphia Section Award (1997); Wyeth-Ayerst Exceptional Achievement Award (1992); and others.

LAXAI (www.laxai.com) provides services in Clinical Research, Medicinal Chemistry, Biology, Process R&D and Analytical Services, Strategic Resourcing and Training to the Biopharmaceutical and Agrochemical Companies. LAXAI offers a unique value proposition to clients in their drug discovery and development initiatives through innovative global partnership models.


'/>"/>
SOURCE LAXAI
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cellular Dynamics International Appoints Leroy Hood, M.D., Ph.D., and George Church, Ph.D., to its Scientific Advisory Board
2. EGEN, Inc. Announces the Promotion of Jason Fewell, Ph.D., to Vice-President of Preclinical Research and Development
3. EGEN, Inc. Announces the Promotion of Khursheed Anwer, Ph.D., to President and Chief Scientific Officer
4. Cequent Names F. Stephen Laroux, Ph.D., Director, Immunology and Inflammatory Diseases
5. SENOMYX ANNOUNCES APPOINTMENT OF DAVID L. LINEMEYER, PH.D., AS VICE PRESIDENT, BIOLOGY
6. ALS Therapy Development Institute, the Worlds Largest Non-Profit Biotech, Appoints Steve Perrin, Ph.D., as Chief Executive Officer
7. Artemis Health Hires Richard Rava, Ph.D., as Senior Vice President of Research and Development
8. ALine, Inc. Expands Management, Adding Roger Anderson, Ph.D., as VP of Operations
9. James L. Wittliff, Ph.D., FACB, to Present Predicting Breast Cancer Outcome with Gene Expression Signatures on the Ziplex(R) System at the Association for Molecular Pathology Conference, October 30
10. SENOMYX CO-FOUNDER AND SCIENTIFIC ADVISORY BOARD MEMBER ROGER TSIEN, PH.D., AWARDED NOBEL PRIZE IN CHEMISTRY
11. Two Luminaries Join Cequent Scientific Advisory Board: Judy Lieberman, M.D. Ph.D., and Patrice Courvalin, M.D.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 ... London (ICR) and University of ... prognostic tool to risk-stratify patients with multiple myeloma (MM), in ... nine . The University of Leeds ... by Myeloma UK, and ICR will perform the testing services ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today announced that ... SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B VHH13 ... cross the cell membrane and bind intracellular STAT3 and inhibit its function. Dysregulation ...
(Date:10/10/2017)... , ... October 10, 2017 , ... ... Center’s FirstHand program has won a US2020 STEM Mentoring Award. Representatives of the ... for Excellence in Volunteer Experience from US2020. , US2020’s mission is to change ...
(Date:10/10/2017)... 10, 2017 SomaGenics announced the receipt of ... develop RealSeq®-SC (Single Cell), expected to be the first ... (including microRNAs) from single cells using NGS methods. The ... to accelerate development of approaches to analyze the heterogeneity ... "New techniques for measuring levels of mRNAs in individual ...
Breaking Biology Technology:
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/29/2017)... March 29, 2017  higi, the health IT company ... North America , today announced a Series ... acquisition of EveryMove. The new investment and acquisition accelerates ... tools to transform population health activities through the collection ... higi collects and secures data today on ...
(Date:3/24/2017)... Research and Markets has announced the addition of the "Global ... to 2025" report to their offering. ... The Global Biometric Vehicle Access System Market ... the next decade to reach approximately $1,580 million by 2025. ... for all the given segments on global as well as regional ...
Breaking Biology News(10 mins):